The short version
SS-31 stands out in the research peptide world for one key reason: it has actually been through proper human clinical trials. Not just animal studies or test-tube research — real phase 2 and phase 3 trials, in people with measurable conditions, with monitored outcomes. That does not make it approved or risk-free, but it puts it in a different category of evidence than most compounds in this space. The results across its trial programme have been mixed rather than uniformly positive, and it has not yet achieved an approval. But it is one of the most rigorously studied mitochondrial compounds available for research.
How it works — in plain English
SS-31 is engineered to home in on the inner membrane of your mitochondria — concentrating there at 1,000 to 5,000 times the levels found elsewhere in the cell. Once there, it binds and stabilises a specific membrane component called cardiolipin, which holds the entire energy production chain in place. As cardiolipin deteriorates with age or disease, energy production drops and cellular waste products accumulate. SS-31 repairs the foundation rather than just compensating for it downstream.
What the research actually shows
SS-31 has been tested across multiple conditions in human trials — Barth syndrome, primary mitochondrial myopathy, heart failure, kidney injury, and age-related macular degeneration.
In Barth syndrome — a rare genetic heart disease — a phase 2/3 trial showed improvements in exercise capacity and quality of life after 48 weeks of treatment. The compound has received FDA Rare Pediatric Disease designation, which indicates the agency considers the development programme credible enough to support. Across other conditions the results have been more variable, with some trials not meeting their primary endpoints.